Hemostemix (HEM) Stock Price Up 15%
Hemostemix Inc (CVE:HEM)’s share price rose 15% on Thursday . The company traded as high as C$0.12 and last traded at C$0.12. Approximately 847,550 shares were traded during trading, an increase of 211% from the average daily volume of 272,336 shares. The stock had previously closed at C$0.10.
About Hemostemix (CVE:HEM)
Hemostemix Inc, a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia.
Recommended Story: The Discount Rate – What You Need to Know
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.